Enveric Biosciences, Inc.

Enveric Biosciences (NASDAQ: $ENVB), a new approach to solving mental health challenges.

[Enveric Biosciences, Inc. @Enveric_Bio]

The recent U.S. executive order focused on accelerating research and regulatory review of psychedelic therapies has sparked renewed discussion across the neuropsychiatric sector. Read more: https://t.co/6u9qJscLgm

[Enveric Biosciences, Inc. @Enveric_Bio]

Despite decades of innovation, approximately one-third of patients with depression do not respond adequately to existing treatments.

Treatment-resistant depression remains one of the largest unmet needs in medicine and a major driver of innovation across neuroscience.

Researchers continue exploring novel mechanisms that may address the underlying biology of these disorders rather than simply managing symptoms.

Source:
https://t.co/1sX75T3Sk3
#DepressionResearch #MentalHealth #Biotech #Neuroscience

[Enveric Biosciences, Inc. @Enveric_Bio]

Enveric has initiated IND-enabling genotoxicity studies for its lead neuroplastogen candidate, EB-003, an important step in the regulatory pathway toward first-in-human clinical trials.
https://t.co/x1fL5b36Gl $ENVB

[Enveric Biosciences, Inc. @Enveric_Bio]

As interest in psychedelic-inspired therapies continues to grow, a new question is emerging: Can these treatments scale?

Read more:
https://t.co/PjYksov4eO

[Enveric Biosciences, Inc. @Enveric_Bio]

A recently published Nature paper suggests that different signalling pathways downstream of the 5-HT2A receptor may drive distinct biological effects, including neuroplasticity and hallucination.
Read the research:
https://t.co/4102u3pRdS
#Neuroplastogens #Neuroscience #MentalHealth #DrugDevelopment #Biotech

[Enveric Biosciences, Inc. @Enveric_Bio]

A new Reuters feature examines how the recent U.S. executive order focused on accelerating psychedelic drug development is driving renewed investor attention across the neuropsychiatric treatment landscape.

Read the Reuters feature: https://t.co/PjYksov4eO

[Enveric Biosciences, Inc. @Enveric_Bio]

A new feature from Labiotech explores the growing momentum behind next-generation antidepressants, including emerging neuroplastogens designed to promote neuroplasticity while improving scalability and accessibility across healthcare systems.
https://t.co/EVm0HNiaJl $ENVB

[Enveric Biosciences, Inc. @Enveric_Bio]

EB-003 has the potential to be a fast-acting neuroplastogen utilizing a differentiated dual-pathway mechanism that activates therapeutic signaling downstream of the 5-HT2A receptor, potentially separating therapeutic benefits from hallucinations. https://t.co/TVzfrj3a0s $ENVB

[Enveric Biosciences, Inc. @Enveric_Bio]

Enveric today announced positive preclinical phototoxicity results for EB-003, with analysis showing no photoreactive potential.

This marks another important preclinical safety assessment milestone as Enveric continues to de-risk EB-003, its lead neuroplastogen candidate designed to promote neuroplasticity without hallucinogenic effects for neuropsychiatric disorders including depression, anxiety and PTSD.

Read the full release: https://t.co/phpVkUQKVJ

$ENVB #Neuroplastogens #Biotech #MentalHealth #DrugDevelopment #ClinicalTrials

[Enveric Biosciences, Inc. @Enveric_Bio]

Enveric today reported financial results for the first quarter ended March 31, 2026, and provided a comprehensive business update. See it here: https://t.co/JotCCws53N

[Enveric Biosciences, Inc. @Enveric_Bio]

Enveric's EB-003 is a differentiated therapeutic candidate w/ dual agonism at the 5-HT2A and 5-HT1B receptors, designed to separate the therapeutic benefits of psychedelics from hallucinogenic effects for the potential treatment of depression, anxiety, & PTSD. https://t.co/kz1lXBKxTv $ENVB

[Enveric Biosciences, Inc. @Enveric_Bio]

Enveric CEO Joseph Tucker, Ph.D., comments on the expansion of the Company's IP portfolio with a new US patent pertaining to the EVM301 Series of molecules. For more details: https://t.co/oKOk8dazwk $ENVB

[Enveric Biosciences, Inc. @Enveric_Bio]

Enveric has announced that the USPTO issued to Enveric US Patent No. 12,605,361 (the ‘361 patent) pertaining to the Company’s EVM301 Series of molecules being developed as potential treatments for mental health disorders. Learn more here: https://t.co/oKOk8dazwk $ENVB

[Enveric Biosciences, Inc. @Enveric_Bio]

Our CEO, Dr. Joseph Tucker, sat down with Clinical Leader to discuss the White House's recently issued executive order aimed at accelerating the use of #psychedelics in clinical research and what it means for the industry. Read it here: https://t.co/POYxl4Gsd8 $ENVB

[Enveric Biosciences, Inc. @Enveric_Bio]

Psychedelic-inspired medicine has the potential to reshape mental health care. Neuroplastogens like EB-003 are emerging as a potential new approach to treatment by increasing neuroplasticity without hallucinations, making the treatment more scalable. https://t.co/k6E9i7wbTo $ENVB

[Enveric Biosciences, Inc. @Enveric_Bio]

.@microdosehq highlights new positive results for Enveric’s EB-003 in a PTSD model and how its dual mechanism of action has the potential to redefine PTSD treatment at a time when regulators and federal agencies signal the need for novel approaches. Read here: https://t.co/SHajyeL5bv $ENVB

[Enveric Biosciences, Inc. @Enveric_Bio]

A recent U.S. executive order supporting research into psychedelic-inspired therapies highlights the growing focus on PTSD & reinforces opportunity for neuroplastogens such as EB-003, designed to deliver psychedelic-associated benefits without hallucinations. https://t.co/PZ2u7aWF1X $ENVB

[Enveric Biosciences, Inc. @Enveric_Bio]

Our CEO, Joseph Tucker, PhD, comments on positive results for EB-003 in a PTSD model and the potential benefits of its dual-mechanism of action. Find out more: https://t.co/1gCJemiybm $ENVB

[Enveric Biosciences, Inc. @Enveric_Bio]

Enveric highlighted preclinical data for EB-003 in which a single dose significantly reduced context-induced freezing behavior one hour post-dose. These results suggest a rapid reduction in conditioned fear responses in a validated preclinical model of PTSD. https://t.co/PZ2u7aWF1X $ENVB

[Enveric Biosciences, Inc. @Enveric_Bio]

A new executive order is accelerating #MentalHealth treatments and signaling support for #psychedelic therapies. @microdosehq explains why a faster FDA framework could make non-hallucinogenic approaches with scalable potential like EB-003 even more critical. https://t.co/eOY04kSKyV $ENVB